Cancer Is Not a Single Moment

When a patient is diagnosed with cancer, we often rely on a single snapshot. A biopsy is taken, the tumor is analyzed, and a treatment plan is created based on that information. This approach has guided clinical care for many years, but it has a limitation. It assumes that cancer is stable.

In reality, cancer is constantly changing. It evolves under pressure from treatment, the immune system, and its surrounding environment. A tumor that looks one way at diagnosis may behave very differently months or years later.

This is why I believe we must begin to think about cancer not as a fixed condition, but as a process that unfolds over time.

What Epigenetics Reveals About Change

Epigenetics offers a powerful way to study this process. While genetic mutations are relatively stable, epigenetic changes are dynamic. They can shift in response to therapy, stress, and environmental signals.

These changes include DNA methylation, histone modification, and chromatin remodeling. Together, they control which genes are active and which are silent. In breast cancer, for example, epigenetic regulation determines whether a tumor expresses the estrogen receptor and remains sensitive to hormone therapy.

In my research, I have seen how epigenetic silencing of key genes like ESR1 can develop over time, especially under the pressure of endocrine treatment. This does not happen all at once. It is a gradual shift, often invisible at the beginning but significant in its long-term impact.

By tracking these changes over time, we can begin to understand how tumors adapt and why they become resistant.

The Value of Longitudinal Profiling

Longitudinal profiling means collecting and analyzing biological data from the same patient at multiple time points. Instead of relying on a single biopsy, we follow the tumor as it evolves.

This approach can reveal patterns that would otherwise be missed. For example:

• A tumor may start as hormone receptor-positive but gradually lose receptor expression
• Epigenetic markers associated with drug resistance may appear before clinical relapse
• Different subpopulations of cells may emerge and compete within the tumor

By observing these changes, we can identify early warning signs of treatment failure and adjust our strategy before the disease progresses.

Learning From Treatment Pressure

Every therapy we use creates pressure on cancer cells. Some cells die, while others survive and adapt. This process is similar to natural selection. The strongest or most adaptable cells become dominant over time.

Epigenetic changes play a key role in this adaptation. They allow cancer cells to switch gene programs without needing new mutations. This makes the process faster and more flexible.

For example, under hormone therapy, some breast cancer cells may reduce their dependence on estrogen signaling by silencing ESR1. Others may activate alternative survival pathways. These changes can be subtle at first, but they can lead to full resistance if not addressed.

Longitudinal profiling helps us see these shifts as they happen, rather than after resistance is already established.

Moving Toward Adaptive Treatment

If we can track how tumors evolve, we can begin to design adaptive treatment strategies. Instead of following a fixed treatment plan, we adjust therapy based on how the tumor is responding in real time.

This might include:

• Switching therapies when early signs of resistance appear
• Combining treatments to prevent the emergence of resistant cell populations
• Introducing epigenetic therapies to restore sensitivity to existing treatments

This approach requires close monitoring and strong collaboration between researchers and clinicians. It also requires tools that can measure epigenetic changes quickly and accurately.

New Tools for Real-Time Monitoring

Advances in technology are making longitudinal profiling more practical. Techniques such as liquid biopsy allow us to analyze tumor-derived DNA in the blood, reducing the need for repeated tissue biopsies.

We can now measure changes in DNA methylation patterns, track circulating tumor cells, and analyze gene expression profiles over time. These tools provide a more complete picture of how the disease is evolving.

In the future, I believe we will integrate these data into predictive models that help guide clinical decisions. Instead of reacting to visible disease progression, we will anticipate it.

Challenges We Must Address

While the potential of longitudinal epigenetic profiling is exciting, there are still challenges to overcome.

First, we need standardized methods for collecting and analyzing epigenetic data. Variability in techniques can make it difficult to compare results across studies.

Second, we must ensure that these approaches are accessible and cost-effective. Advanced profiling should not be limited to a small number of research centers.

Third, we need to train clinicians and scientists to interpret complex data. Understanding how epigenetic changes relate to treatment decisions requires both technical knowledge and clinical insight.

These challenges are real, but they are not insurmountable. With collaboration and investment, we can build systems that support this new approach.

Teaching a New Way of Thinking

As an educator, I encourage my students to think about cancer in terms of time and change. I ask them to consider not just what a tumor is, but what it might become.

This perspective changes how we design experiments and how we interpret results. It also prepares the next generation of scientists to work in a field that is becoming increasingly dynamic and data-driven.

When students understand that cancer is evolving, they begin to ask deeper questions. They look for patterns, transitions, and interactions. This is the kind of thinking we need to move the field forward.

Seeing the Full Story

A single snapshot of cancer can tell us a great deal, but it cannot tell us everything. To truly understand the disease, we must follow it over time. We must observe how it responds, adapts, and sometimes escapes our best efforts.

Longitudinal epigenetic profiling gives us a way to do this. It allows us to see the full story of cancer, not just one chapter.

By mapping these changes, we can move toward a future where treatment is not only personalized, but also responsive and adaptive. This is how we improve outcomes and give patients the best possible chance for long-term success.